Patients voice concern about consequences of a Genzyme takeover

08/9/2010 | Boston Globe (tiered subscription model), The

Some patients who use Genzyme's treatments are worried that their close relationship with the biotech firm will end if it is acquired by a bigger company. Meanwhile, Genzyme's strategy of reaching out and regularly checking on patients has prompted other drug companies to try the same to expand their share of the market for rare illnesses, such as Pompe and Gaucher diseases.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX